Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori
Author:
- 4 August 2017
- journal article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 46 (5) , 550-551
Abstract
Linked ContentThis article is linked to Jung and Bardhan papers. To view these articles visit https://doi.org/10.1111/apt.14206 and https://doi.org/10.1111/apt.14130.Keywords
This publication has 8 references indexed in Scilit:
- Systematic review with meta‐analysis: the efficacy of vonoprazan‐based triple therapy on Helicobacter pylori eradicationAlimentary Pharmacology & Therapeutics, 2017
- The Toronto Consensus for the Treatment of Helicobacter pylori Infection in AdultsGastroenterology, 2016
- Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind studyGut, 2016
- Review article: the global emergence ofHelicobacter pyloriantibiotic resistanceAlimentary Pharmacology & Therapeutics, 2015
- Eradication Rates of Helicobacter pylori in Korea Over the Past 10 years and Correlation of the Amount of Antibiotics Use: Nationwide SurveyHelicobacter, 2015
- Editorial: towards extended acid suppression - the search continuesAlimentary Pharmacology & Therapeutics, 2015
- Acid‐inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects ‐ a randomised open‐label cross‐over studyAlimentary Pharmacology & Therapeutics, 2015
- Meta‐analysis: high‐dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradicationAlimentary Pharmacology & Therapeutics, 2008